Search Books
Information Security Manage… Frontiers in Queueing: Mode…

Generic Drug Product Development: Bioequivalence Issues (Drugs and the Pharmaceutical Sciences)

Author Isadore Kanfer, Leon Shargel
Publisher CRC Press
Category Business & Economics
📄 Viewing lite version Full site ›
🌎 Shop on Amazon — choose country
157.95 USD
🛒 Buy New on Amazon 🇺🇸 🏷 Buy Used — $46.70

✓ Usually ships in 24 hours

Share:
Book Details
PublisherCRC Press
ISBN / ASIN0849377846
ISBN-139780849377846
AvailabilityUsually ships in 24 hours
Sales Rank3,916,979
MarketplaceUnited States 🇺🇸

Description

The assessment of bioequivalence is an important process whereby the bioavailability of a generic drug product is compared with its brand-name counterpart. Generic pharmaceutical products must be approved as therapeutic equivalents to the brand name alternative in order to be interchangeable. The demonstration of bioequivalence is an important component of therapeutic equivalence. Bioequivalence studies are very expensive, time consuming and always have the possibility of failure. The objective of this textbook is to describe some of those specific bioequivalence issues which need to be considered for the design and conduct of bioequivalence studies. By exploring scientific, legal, and international regulatory challenges, Generic Drug Development, discusses the use of alternative approaches to the measurement of plasma drug concentrations for the demonstration of bioequivalence, and covers bioequivalence procedures for drug products that are not easily assessed - based upon the physical and chemical properties of the active drug and the nature of the drug product.
Towers of gold, feet of clay: The Canadian banks
View
The Twelve Organizational Capabilities
View
The Looting Machine: Warlords, Tycoons, Smugglers and …
View
The Real-Life MBA: The No-Nonsense Guide to Winning th…
View
Collins Cape Revision Guide - Management of Business (…
View
Glencoe Mathematics for Business and Personal Finance,…
View
Economics: Ap Edition (A/P Economics)
View
Money, Banking and Financial Markets
View
Money, Banking, and Financial Markets
View